These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 33661190)

  • 1. Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922).
    Moschos SJ; Eroglu Z; Khushalani NI; Kendra KL; Ansstas G; In GK; Wang P; Liu G; Collichio FA; Googe PB; Carson CC; McKinnon K; Wang HH; Nikolaishvilli-Feinberg N; Ivanova A; Arrowood CC; Garrett-Mead N; Conway KC; Edmiston SN; Ollila DW; Serody JS; Thomas NE; Ivy SP; Agrawal L; Dees EC; Abbruzzese JL
    Melanoma Res; 2021 Apr; 31(2):162-172. PubMed ID: 33661190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brentuximab Vedotin Plus Ibrutinib in Relapsed and Refractory Hodgkin Lymphoma.
    Mei M; Tsai NC; Palmer J; Armenian S; Chen R; Rosen S; Forman S; Popplewell L; Kwak L; Martin P; Maddocks K; Bond D; Herrera AF
    Clin Lymphoma Myeloma Leuk; 2024 Aug; 24(8):537-542. PubMed ID: 38693037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ibrutinib Blocks YAP1 Activation and Reverses BRAF Inhibitor Resistance in Melanoma Cells.
    Misek SA; Newbury PA; Chekalin E; Paithankar S; Doseff AI; Chen B; Gallo KA; Neubig RR
    Mol Pharmacol; 2022 Jan; 101(1):1-12. PubMed ID: 34732527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
    Sharman JP; Brander DM; Mato AR; Ghosh N; Schuster SJ; Kambhampati S; Burke JM; Lansigan F; Schreeder MT; Lunin SD; Zweibach A; Shtivelband M; Travis PM; Chandler JC; Kolibaba KS; Sportelli P; Miskin HP; Weiss MS; Flinn IW
    Lancet Haematol; 2021 Apr; 8(4):e254-e266. PubMed ID: 33631112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel ibrutinib analogues to treat malignant melanoma.
    Ren S; Wang X; Song J; Jin G
    Bioorg Chem; 2021 Dec; 117():105419. PubMed ID: 34689082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-infiltrating lymphocytes are functionally inactivated by CD90+ stromal cells and reactivated by combined Ibrutinib and Rapamycin in human pleural mesothelioma.
    Yang H; Berezowska S; Dorn P; Zens P; Chen P; Peng RW; Marti TM; Kocher GJ; Schmid RA; Hall SRR
    Theranostics; 2022; 12(1):167-185. PubMed ID: 34987640
    [No Abstract]   [Full Text] [Related]  

  • 7. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.
    Fan F; Yoo HJ; Stock S; Wang L; Liu Y; Schubert ML; Wang S; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
    Int J Cancer; 2021 Jan; 148(2):419-428. PubMed ID: 32683672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.
    Jones JA; Mato AR; Wierda WG; Davids MS; Choi M; Cheson BD; Furman RR; Lamanna N; Barr PM; Zhou L; Chyla B; Salem AH; Verdugo M; Humerickhouse RA; Potluri J; Coutre S; Woyach J; Byrd JC
    Lancet Oncol; 2018 Jan; 19(1):65-75. PubMed ID: 29246803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma.
    Liu M; Deng H; Mu J; Li Q; Pu Y; Jiang Y; Deng Q; Qian Z
    Cancer Sci; 2021 Jul; 112(7):2642-2651. PubMed ID: 33932067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ibrutinib treatment inhibits breast cancer progression and metastasis by inducing conversion of myeloid-derived suppressor cells to dendritic cells.
    Varikuti S; Singh B; Volpedo G; Ahirwar DK; Jha BK; Saljoughian N; Viana AG; Verma C; Hamza O; Halsey G; Holcomb EA; Maryala RJ; Oghumu S; Ganju RK; Satoskar AR
    Br J Cancer; 2020 Mar; 122(7):1005-1013. PubMed ID: 32025027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients.
    McCulloch R; Lewis D; Crosbie N; Eyre TA; Bolam S; Arasaretnam A; Creasey T; Goradia H; McMillan A; Dawi S; Harrison S; Miles O; Robinson A; Dutton D; Wilson MR; McKay P; Follows G; Phillips N; Patmore R; Lambert J; Bishton M; Osborne W; Johnston R; Kirkwood AA; Rule S
    Br J Haematol; 2021 Apr; 193(2):290-298. PubMed ID: 33620106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conjugate of ibrutinib with a TLR7 agonist suppresses melanoma progression and enhances antitumor immunity.
    Ren S; Wang X; Jin G
    Int J Biol Sci; 2022; 18(1):166-179. PubMed ID: 34975325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma.
    Klemen ND; Wang M; Rubinstein JC; Olino K; Clune J; Ariyan S; Cha C; Weiss SA; Kluger HM; Sznol M
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32209601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Janus kinases restrain chronic lymphocytic leukemia cells in patients on ibrutinib: Results of a phase II trial.
    Spaner DE; Luo Y; Wang G; Gallagher J; Tsui H; Shi Y
    Cancer Med; 2021 Dec; 10(24):8789-8798. PubMed ID: 34791813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma.
    Kumar A; Vardhana S; Moskowitz AJ; Porcu P; Dogan A; Dubovsky JA; Matasar MJ; Zhang Z; Younes A; Horwitz SM
    Blood Adv; 2018 Apr; 2(8):871-876. PubMed ID: 29669753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic effect of ibrutinib and CD19 CAR-T cells on Raji cells in vivo and in vitro.
    Liu M; Wang X; Li Z; Zhang R; Mu J; Jiang Y; Deng Q; Sun L
    Cancer Sci; 2020 Nov; 111(11):4051-4060. PubMed ID: 32876369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.
    Wierda WG; Allan JN; Siddiqi T; Kipps TJ; Opat S; Tedeschi A; Badoux XC; Kuss BJ; Jackson S; Moreno C; Jacobs R; Pagel JM; Flinn I; Pak Y; Zhou C; Szafer-Glusman E; Ninomoto J; Dean JP; James DF; Ghia P; Tam CS
    J Clin Oncol; 2021 Dec; 39(34):3853-3865. PubMed ID: 34618601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
    Allan JN; Shanafelt T; Wiestner A; Moreno C; O'Brien SM; Li J; Krigsfeld G; Dean JP; Ahn IE
    Br J Haematol; 2022 Feb; 196(4):947-953. PubMed ID: 34865212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
    Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
    JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma.
    Graf SA; Cassaday RD; Morris K; Voutsinas JM; Wu QV; Behnia S; Lynch RC; Krakow E; Rasmussen H; Chauncey TR; Kanan S; Soma L; Smith SD; Gopal AK
    Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):176-181. PubMed ID: 33358575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.